Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced a 50‑for‑1 reverse stock split that will take effect at 12:01 a.m. on March 6, 2026. The split consolidates every 50 shares into one, eliminates fractional shares, and pays cash to holders who would otherwise receive a fraction of a share.
The reverse split is intended to raise the share price above Nasdaq’s $1.00 minimum bid‑price requirement and preserve the company’s listing on the Nasdaq Global Market. The split will not change the company’s ticker symbol (TVGN) or the total number of shares outstanding, but it will issue a new CUSIP (88165K200).
Tevogen’s board approved the split after shareholders voted in favor on February 19, 2026. The company has faced recurring Nasdaq compliance challenges, having regained compliance in October 2024 without a reverse split, then receiving a deficiency notice in September 2025 with a March 23, 2026 deadline. The reverse split is a last‑minute measure to avoid delisting.
Tevogen is a clinical‑stage specialty immunotherapy company with no products approved for commercial sale. The company has reported ongoing losses and negative free cash flow, and its capital‑intensive pipeline requires substantial funding. The reverse split does not address these underlying business issues but is a necessary step to maintain market access and liquidity.
Investors and market participants view the reverse split as a cosmetic remedy that does not resolve the company’s long‑term financial challenges. The action underscores the need for Tevogen to secure additional capital and demonstrate progress in its pipeline to restore confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.